Introduction
Legionella pneumophila causes about 1-5% of cases of pneumonia and carries a mortality rate of 10-30%.
1,2 Erythromycin is considered the treatment of choice and experimental data indicate that fluoroquinolones and rifampicin are also effective. [3] [4] [5] These agents are active against intracellular L. pneumophila. Mutations inducing resistance to these antibiotics occur in vitro at a rate of 10 7 to 10 10 .
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To determine whether increased resistance to erythromycin, rifampicin or ciprofloxacin explains, in part, the high mortality rate in legionnaires' disease, we examined 98 consecutive clinical isolates for susceptibility to these antibiotics.
Materials and methods

Bacterial strains
Ninety-eight isolates of L. pneumophila were obtained between 1989 and 1995 from the respiratory tract of 96 patients, in 19 different hospitals in the Paris area. With a few exceptions, the cases were not epidemiologically related. Of these isolates, 82 belonged to serogroup 1, eight to serogroup 3, six to serogroup 5 and one to serogroup 6. The isolates were stored at 80°C, after one subculture on buffered charcoal yeast extract agar.
Agar dilution susceptibility testing
The basal medium was buffered starch yeast extract agar (BSYE). 4 Standard laboratory powders of erythromycin (Abbott Laboratories, Rungis, France), rifampicin (Marion Merrel Dow, Levallois, France) and ciprofloxacin (Bayer, Puteaux, France) were used to prepare stock solutions. L. pneumophila strains were inoculated on buffered charcoal yeast extract agar and incubated for 48 h at 37°C with 2.5% CO 2 and harvested in sterile distilled water: turbidity was then adjusted to 0.5 McFarland standard. The suspensions were subsequently diluted 1:10 in distilled water and inoculated with a Steers replicator on to antimicrobial agentcontaining BSYE plates. The plates were incubated at 37°C for 48 h in air. The MIC was recorded as the lowest drug concentration at which there was no visible growth. All determinations were carried out in duplicate.
Staphylococcus aureus ATCC 25923 was inoculated in parallel on to antimicrobial agent-containing MuellerHinton agar plates as well as BSYE plates, to determine whether BSYE inhibited the activity of the antibiotics.
Results and discussion
The MICs of erythromycin, rifampicin and ciprofloxacin are reported in the Table. All isolates were inhibited by low concentrations of ciprofloxacin and rifampicin, and all were susceptible to erythromycin with MICs in the range 0.06-1 mg/L. These results are similar to data from the literature, 7, 8 though the possibility that resistance to these antimicrobial agents might only be seen in legionellae grown intracellularly cannot be excluded. As charcoal can inhibit the activity of some antibiotics, 8, 9 we used the charcoal-free medium described by Saito et al. 4 The ability of all Legionella strains to grow on BSYE agar is controversial 3 and may be related to the passage history of the strains. We, like others, 8 have found that all L. pneumophila isolates grow well on this medium. Moreover, the MICs for the control S. aureus strain on BSYE did not differ significantly from those obtained on Mueller-Hinton agar. 
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This study of 98 consecutive clinical isolates of L. pneumophila failed to detect resistance to erythromycin, ciprofloxacin and rifampicin. The mortality rate among the patients infected by these strains was 27%. 10 Our results indicate that therapeutic failures in these patients were not related to reduced susceptibility to commonly used antimicrobial agents.
There is no carrier state for legionella. In addition, there is no evidence of person-to-person spread of legionnaires' disease and disease generally occurs after exposure to aerosols of legionella-colonized water. For these reasons, the potential for exposure of the organism to antibiotics, before infections, is low. Therefore, the lack of resistance to antibiotics in clinical isolates is probably related to the lack of selective pressure within the natural environment of the organism.
In two cases in this series, isolates were obtained at the start of therapy and several days later and no change in susceptibility to antibiotics was found. Likewise, Edelstein found no increase in resistance to rifampicin during treatment of the experimental disease in guinea-pigs. 5 In conclusion, the main cause of therapeutic failure in legionnaires' disease is probably late treatment. Indeed, two recent studies indicate that appropriate therapy is only given after an average of 7 days. 2, 10 
